Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BIOD-531 PK/PD in T2DM with Severe Insulin Resistance
NCT02324309Phase 2Completed
- Sponsor
- Biodel Inc.
- Start
- May 2014
- Primary completion
- Nov 2014
- Modality
- Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, single-blind trial of Insulin (recombinant human, concentrated, BIOD-531 formulation) in type 2 diabetes mellitus (T2DM) (4 arms), sponsored by Biodel Inc. Primary endpoint: Post-breakfast glucose exposure (AUC). Started May 2014; status: completed.
02
Drugs
Insulin (recombinant human, concentrated, BIOD-531 formulation)
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT02324309.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02324309.